146 related articles for article (PubMed ID: 37355392)
41. Pretreatment Primary Tumor Stage is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy.
La Mendola R; Bencivenga M; Torroni L; Alberti L; Sacco M; Casella F; Ridolfi C; Simoni N; Micera R; Pavarana M; Verlato G; Giacopuzzi S
Ann Surg Oncol; 2021 Jun; 28(6):3034-3043. PubMed ID: 33078313
[TBL] [Abstract][Full Text] [Related]
42. [Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)].
Schmidt T; Sisic L; Sterzing F; Haag GM; Kunzmann R; Grenacher L; Weichert W; Jäger D; Büchler MW; Ott K
Chirurg; 2015 Oct; 86(10):955-62. PubMed ID: 25715974
[TBL] [Abstract][Full Text] [Related]
43. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
Eyck BM; van Lanschot JJB; Hulshof MCCM; van der Wilk BJ; Shapiro J; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van der Sangen MJC; Rozema T; Ten Kate FJW; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
J Clin Oncol; 2021 Jun; 39(18):1995-2004. PubMed ID: 33891478
[TBL] [Abstract][Full Text] [Related]
44. Curative treatment for esophageal cancer: Vancouver Island Cancer Centre experience from 1993 to 1998.
Wilson KS; Wilson AG; Dewar GJ
Can J Gastroenterol; 2002 Jun; 16(6):361-8. PubMed ID: 12096299
[TBL] [Abstract][Full Text] [Related]
45. Salvage radiotherapy for postoperative loco-regional recurrence of esophageal cancer.
Yamashita H; Nakagawa K; Tago M; Nakamura N; Shiraishi K; Ohtomo K
Dis Esophagus; 2005; 18(4):215-20. PubMed ID: 16128776
[TBL] [Abstract][Full Text] [Related]
46. Definitive Chemoradiotherapy Compared to Neoadjuvant Chemoradiotherapy With Esophagectomy for Locoregional Esophageal Cancer: National Population-based Cohort Study.
Kamarajah SK; Phillips AW; Hanna GB; Low D; Markar SR
Ann Surg; 2022 Mar; 275(3):526-533. PubMed ID: 32865948
[TBL] [Abstract][Full Text] [Related]
47. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
[TBL] [Abstract][Full Text] [Related]
48. Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
Huang PM; Hsu FM; Lin CC; Hsu CH; Cheng JC; Lee JM
Dig Surg; 2018; 35(2):104-110. PubMed ID: 28675905
[TBL] [Abstract][Full Text] [Related]
49. Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma.
Lv J; Cao XF; Zhu B; Ji L; Tao L; Wang DD
World J Gastroenterol; 2009 Oct; 15(39):4962-8. PubMed ID: 19842230
[TBL] [Abstract][Full Text] [Related]
50. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
[TBL] [Abstract][Full Text] [Related]
51. A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2.
van der Zijden CJ; Lagarde SM; Hermus M; Kranenburg LW; van Lanschot JJB; Mostert B; Nuyttens JJME; Oudijk L; van der Sluis PC; Spaander MCW; Valkema MJ; Valkema R; Wijnhoven BPL;
BMC Cancer; 2023 Apr; 23(1):327. PubMed ID: 37038138
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
Darling GE; Li F; Patsios D; Massey C; Wallis AG; Coate L; Keshavjee S; Pierre A; De Perrot M; Yasufuku K; Cypel M; Waddell T
Eur J Cardiothorac Surg; 2015 Nov; 48(5):684-90; discussion 690. PubMed ID: 25567960
[TBL] [Abstract][Full Text] [Related]
53. Local field radiotherapy without elective nodal irradiation for postoperative loco-regional recurrence of esophageal cancer.
Kimoto T; Yamazaki H; Suzuki G; Aibe N; Masui K; Tatekawa K; Sasaki N; Fujiwara H; Shiozaki A; Konishi H; Nakamura S; Yamada K
Jpn J Clin Oncol; 2017 Sep; 47(9):809-814. PubMed ID: 28903531
[TBL] [Abstract][Full Text] [Related]
54. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
[TBL] [Abstract][Full Text] [Related]
55. [A Case of Salvage Chemoradiotherapy for Regional Recurrence after Curative Esophagectomy].
Yamamoto M; Okuno T; Imanishi T; Kanaji S; Yamashita K; Kanemitsu K; Sumi Y; Nakamura T; Suzuki S; Kakeji Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1457-9. PubMed ID: 26805062
[TBL] [Abstract][Full Text] [Related]
56. Esophageal cancer patients' survival after complete response to definitive chemoradiotherapy: a retrospective analysis.
Mori K; Sugawara K; Aikou S; Yamashita H; Yamashita K; Ogura M; Chin K; Watanabe M; Matsubara H; Toh Y; Kakeji Y; Seto Y
Esophagus; 2021 Jul; 18(3):629-637. PubMed ID: 33625649
[TBL] [Abstract][Full Text] [Related]
57. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?
Meguid RA; Hooker CM; Taylor JT; Kleinberg LR; Cattaneo SM; Sussman MS; Yang SC; Heitmiller RF; Forastiere AA; Brock MV
J Thorac Cardiovasc Surg; 2009 Dec; 138(6):1309-17. PubMed ID: 19931663
[TBL] [Abstract][Full Text] [Related]
58. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
[TBL] [Abstract][Full Text] [Related]
59. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
[TBL] [Abstract][Full Text] [Related]
60. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
